Efficacy and safety of diuretics in combination with perindopril in hypertensive stroke patients: Results of the Japan perindopril and diuretics on cerebrovascular disease study (J-PADOC)

Blood Pressure

Volumn 19, Issue SUPPL. 1, 2010, Pages 10-16

  Hasegawa, Yasuhiro ^a   Shimada, Kazuyuki ^b   Yamaguchi, Takenori ^c  

^a ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b JICHI MEDICAL UNIVERSITY   (Japan)

^c NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

Author keywords

Cerebrovascular disease; Diuretics; Hypertension; Perindopril

Indexed keywords

CHLORTALIDONE; CHOLESTEROL; CREATININE; DIURETIC AGENT; GLUCOSE; HYDROCHLOROTHIAZIDE; INDAPAMIDE; MEFRUSIDE; PERINDOPRIL; TRIACYLGLYCEROL; TRICHLORMETHIAZIDE; TRIPAMIDE; URIC ACID;

AGED; ANEMIA; ARTICLE; CEREBROVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; COUGHING; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; KIDNEY DYSFUNCTION; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SIDE EFFECT; STROKE; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; UREA BLOOD LEVEL; UREA NITROGEN BLOOD LEVEL; URIC ACID BLOOD LEVEL;

AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DIURETICS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PERINDOPRIL; STROKE;

EID: 77649171414     PISSN: 08037051     EISSN: 16511999     Source Type: Journal    
DOI: 10.3109/08037050903513497     Document Type: Article

References (17)

1. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358:1033-1041.
2. Chalmers J, Neal B, MacMahon S, on behalf of the PROGRESS Management Committee. PROGRESS (Perindopril Protection Against Recurrent Stroke Study): Regional characteristics of the study population at baseline. J Hypertens. 2000;18:S13-S19.
3. Saito I, Kawabe H, Tsujioka M, Hirose H, Shibata H. Trends in pharmacologic management of hypertension in Japan one year after the publication of the JSH 2000 Guidelines. Hypertens Res. 2002;25:175-178.
4. Yamamoto Y, Sonoyama K, Matsubara K, Furuse M, Yatsuhashi T, Hamada T, et al. The status of hypertension management in Japan in 2000. Hypertens Res. 2002;25:717-725.
5. Hasegawa Y, Yamaguchi T, Omae T, Woodward M, Chalmers J; PROGRESS CT Substudy Investigators. Effects of perindopril- based blood pressure lowering and of patient characteristics on the progression of silent brain infarct: The Perindopril Protection against Recurrent Stroke Study (PROGRESS) CT Substudy in Japan. Hypertens Res. 2004;27:147-156.
6. Dufouil C, Chalmers J, Coskun O; PROGRESS MRI Substudy Investigators. Effects of blood pressure lowering on cerebral white matter hyperintensities in patients with stroke: The PROGRESS (Perindopril Protection Against Recurrent Stroke Study) Magnetic Resonance Imaging Substudy. Circulation. 2005;112:1644-1650.
7. Barzilay JI, Davis BR, Cutler JA, Pressel SL, Whelton PK, Basile J, et al. Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: A report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med. 2006;166:2191-2201.
8. MedDRA® Term selection: Points to consider. Release 3.8 Based on MedDRA Version 10.0. ICH-Endorsed Guide for MedDRA Users. Application to Adverse Drug Reactions / Adverse Events & Medical and Social History & Indications. 2 April 2007. http://www.ich.org/LOB/media/MEDIA3713. pdf (accessed Aug 2, 2007).
9. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206-1252.
10. Ogihara T, Kikuchi K, Matsuoka H, Fujita T, Higaki J, Horiuchi M, et al. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009). Hypertens Res. 2009;32:3-107.
11. Guidelines Committee. 2003 European Society of Hypertension- European Society of Cardiology guidelines for the Management of Arterial Hypertension. J Hypertens. 2003;21: 1011-1053.
12. The ALLHAT Offi cers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981-2997.
13. World Health Organization, International Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens. 2003; 21:1983-1992.
14. Holland OB, Kuhnert L, Campbell WB, Anderson RJ. Synergistic effect of captopril with hydrochlorothiazide for the treatment of low-renin hypertensive black patients. Hypertens. 1983;5:235-239.
15. Weinberger MH. Angiotensin converting enzyme inhibitors enhance the antihypertensive effi cacy of diuretics and blunt or prevent adverse metabolic effects. J Cardiovasc Pharmacol. 1989;13 Suppl 3:1-4.
16. Pollare T, Lithell H, Berne C. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med. 1989;321:868-873.
17. ADVANCE Collaborative Group. Effects of a fi xed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): A randomised controlled trial. Lancet. 2007;370:829-840.